Braunlin, E., Rosenfeld, H., Kampmann, C., Johnson, J., et al. (2013). Enzyme replacement therapy for mucopolysaccharidosis VI: Long-term cardiac effects of galsulfase (Naglazyme®) therapy. Journal of Inherited Metabolic Disease, 36(2), 385 - 394.

Braunlin, E., Rosenfeld, H., Kampmann, C., Johnson, J., et al. (2012). Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme ®) therapy. Journal of Inherited Metabolic Disease.

Harmatz, P., Yu, Z. - F., Giugliani, R., Schwartz, I. V. D., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Inherited Metabolic Disease, 33(1), 51 - 60.

Decker, C., Yu, Z. - F., Giugliani, R., Schwartz, I. V. D., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Pediatric Rehabilitation Medicine, 3(2), 89 - 100.

Harmatz, P., Giugliani, R., D. Schwartz, I. V., Guffon, N., et al. (2008). Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Molecular Genetics and Metabolism, 94(4), 469 - 475.